Core Viewpoint - The company BaiO Saite-B (02315) has seen a nearly 7% increase in stock price, attributed to the completion of the localization of its AI-driven antibody drug research platform, which enhances its core business collaboration with the QianShu WanKang program [1] Group 1 - BaiO Saite-B's stock price rose by 5.08% to HKD 39.72, with a trading volume of HKD 28.32 million [1] - The company announced the successful localization of its AI-driven antibody drug research platform, which is now fully integrated with its core business initiatives [1] - The ongoing integration of the QianShu WanKang program with the AI system is expected to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library [1] Group 2 - The advancements in AI localization are aimed at improving the research efficiency of preclinical PCC molecules for pharmaceutical partners [1] - This development is anticipated to propel the antibody discovery business into a new phase of growth [1]
港股异动 再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署